OM1 earns Frost & Sullivan's 2024 North American New Product Innovation Award for transforming real-world evidence analytics solutions industry with its pioneering ai-powered platforms.

OM1 appoints Catherine Richards as President.

What You Should Know:–  OM1, the leader in real-world insights synthesis and evidence generation for life sciences supporting population and personalized data insights, evidence generation through advanced validated AI platforms, big deep clinical data, registries, and globally recognized thought leadership today announced the new release of its Alzheimer’s disease PremiOM dataset.– OM1 combines multiple real-world data sources – including specialists’ electronic medical records (EMR), medical and pharmacy claims, social determinants of health (SDoH), and mental health assessments – with medical language processing and advanced AI capabilities to generate deep clinical insights for patients with Alzheimer’s disease.OM1: Advancing Alzheimer’s Research with Cutting-Edge Healthcare InnovationOM1 is at the forefront of healthcare innovation, leveraging insights-driven technology and data to revolutionize personalized medicine, evidence generation, and real-world evidence (RWE) research. The company utilizes next-generation AI platforms, regulatory-grade deep longitudinal data, and globally recognized thought leadership to achieve these goals.“We know that the pathogenesis of Alzheimer’s can begin decades before clinical symptoms emerge. And, while exciting, the new disease-modifying therapies entering the market for the first time only have a modest impact on a person’s disease journey if they are already in advanced cognitive decline,” said Carl Marci, MD, Chief Clinical Officer and Managing Director of Mental Health and Neuroscience at OM1. “This, combined with the fact there is no cure, makes early detection and intervention to boost neuro-resiliency in patients even more crucial.”Led by a diverse team of scientists, engineers, researchers, and clinicians with over 30 years of experience in real-world data (RWD) and RWE, OM1 boasts a Real-World Data Cloud encompassing over one million patients. This patient data network advances research by:– Facilitating clinical trial recruitment– Uncovering prescriber trends– Modeling health economics and clinical outcomesIn addition to standard claims data, the dataset includes enriched clinical notes from over 17,000 patients within its national network of specialists treating Alzheimer’s patients. This comprehensive dataset provides deeper insights into patient journeys, enabling earlier intervention.Alzheimer’s disease, a progressive and degenerative brain disorder, impacts memory and other essential mental functions, ultimately affecting an individual’s physical, social, and financial health